Coronavirus Update: New Funding For Valneva, Scotland Looks At Long COVID
Plus, Positive Japan Results For Moderna Vaccine
Executive Summary
France's Valneva raises new funds to progress its inactivated vaccine, while Scotland launches a new study into 'long COVID', Takeda reports positive interim results from a Japanese trial with Moderna's mRNA vaccine, a setback for GC's plasma therapy, and Celltrion begins exporting a therapeutic antibody.